# Vericel Corp: Form 10-Q for the period ended Mar 31, 2019

- Company: [Vericel Corp](/companies/vcel.md) (CIK 887359)
- Form: 10-Q
- Filed: 2019-05-07
- Accepted by EDGAR: May 7, 2019, 17:04 ET
- Period: 2019-03-31
- Accession: 0001628280-19-006102
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/887359/000162828019006102/vericel3311910q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/887359/000162828019006102/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-01-01 to 2019-03-31 | $22.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months, 2019-01-01 to 2019-03-31 | $13.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-01-01 to 2019-03-31 | $3.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-01-01 to 2019-03-31 | $13.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-01-01 to 2019-03-31 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-01-01 to 2019-03-31 | $2.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2019-01-01 to 2019-03-31 | −$2.8m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months, 2019-01-01 to 2019-03-31 | $154.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2019-01-01 to 2019-03-31 | $232.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-03-31 | $35.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-03-31 | $109.6m | us-gaap:AssetsCurrent |
| Total assets | at 2019-03-31 | $141.2m | us-gaap:Assets |
| Current liabilities | at 2019-03-31 | $12.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-03-31 | $38.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-03-31 | $103.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 21,507 characters.

### Overview

Vericel Corporation is a leader in advanced cell therapies for the sports medicine and severe burn care markets, and a developer of cell therapies for use in the treatment of patients with severe diseases and conditions. We currently market two FDA approved autologous cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. We also market Epicel® (cultured epidermal autografts), a permanent skin replacement Humanitarian Use Device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (TBSA).

### Manufacturing

We have a cell-manufacturing facility in Cambridge, Massachusetts which is used for U.S. manufacturing and distribution of MACI and Epicel.

### Product Portfolio

Our approved and marketed products include two approved autologous cell therapy products: MACI, a third generation autologous implant for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients and Epicel, a permanent skin replacement for full thickness burns in adults and pediatrics with greater than or equal to 30% of TBSA, both of which are currently marketed in the U.S. We also own Carticel which is no longer marketed in the U.S. Until 2017, our active product candidate portfolio included ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to dilated cardiomyopathy, or DCM. We have no current plans to continue the development of ixmyelocel-T.

### MACI

MACI is a third generation autologous implant for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. MACI replaced Carticel, an earlier generation ACI product for the treatment and repair of cartilage defects in the knee and was the first FDA-approved autologous cartilage repair product.

In the U.S., the physician target audience which repairs cartilage defects is very concentrated and is comprised of a group of physicians who self-identify as or have the formal specialty of sports medicine physicians. We believe this target audience is approximately 2,500 to 3,000 physicians. In addition to these physicians there is a population of 4,000 to 8,000 general orthopedic surgeons who treat cartilage injuries, although typically at a much lower average volume relative to the sports medicine physicians. As we look to more effectively engage this customer base, we expanded our field force from 40 to 48 representatives, whom we anticipate to be in the field in the second quarter of 2019. Most private payers have a medical policy that covers treatment with MACI with all of the top 30 largest commercial payers having a formal medical policy for MACI or ACI in general. For those private payers which have not yet approved a medical policy for MACI, for medically appropriate cases we can often obtain approval on a case by case basis. For the three months ended March 31, 2019 and 2018, net revenues for MACI were $16.6 million and $12.1 million, respectively.

### Epicel

Epicel is a permanent skin replacement for full thickness burns greater than or equal to 30% of TBSA. Epicel is regulated by the Center for Biologics Evaluation and Research, or CBER of the U.S. Food and Drug Administration, or FDA under medical device authorities, and is the only FDA-approved autologous epidermal product available for large total surface area burns. Epicel was designated as a HUD in 1998 and a Humanitarian Device Exception (HDE) application for the product was submitted in 1999. HUDs are devices that are intended for diseases or conditions that affect fewer than 8,000 individuals annually in the U.S. Under an HDE approval, a HUD cannot be sold for an amount that exceeds the cost of research and development, fabrication and distribution unless certain conditions are met.

A HUD is eligible to be sold for profit after receiving HDE approval if the device meets certain eligibility criteria, including where the device is intended for the treatment of a disease or condition that occurs in pediatric patients and such device is labeled for use in pediatric patients. If the FDA determines that a HUD meets the eligibility criteria, the HUD is permitted to be sold for profit as long as the number of devices distributed in any calendar year does not exceed the Annual Distribution Number (ADN). The ADN is defined as the number of devices reasonably needed to treat a population of 8,000 individuals per year in the U.S.

On February 18, 2016, the FDA approved our HDE supplement to revise the labeled indications of use to specifically include pediatric patients and to add pediatric labeling. The revised product label also now specifies that the probable benefit of Epicel, mainly related to survival, was demonstrated in two Epicel clinical experience databases and a physician-sponsored study comparing outcomes in patients with massive burns treated with Epicel relative to standard care. Due to the change in the label to specifically include use in pediatric patients, Epicel is no longer subject to the HDE profit restrictions. In conjunction with adding the pediatric labeling and meeting the pediatric eligibility criteria, the FDA has determined the ADN number for Epicel is 360,400 which is approximately 45 times larger than the volume of grafts sold in 2018. We currently have a 5-person field force. For the three months ended March 31, 2019 and 2018, net revenues for Epicel were $5.2 million and $6.0 million, respectively.

### Ixmyelocel-T

Our preapproval stage portfolio includes ixmyelocel-T, a unique multicellular therapy derived from an adult patient’s own bone marrow which utilizes our proprietary, highly automated and scalable manufacturing system. This multicellular therapy was developed for the treatment of advanced heart failure due to DCM.

Ixmyelocel-T has been granted a U.S. Orphan Drug designation by the FDA for the treatment of DCM. We completed enrolling and treating patients in our completed Phase 2b ixCELL-DCM study in February, 2015. Patients were followed for 12 months for the primary efficacy endpoint of major cardiac adverse events, or MACE. On March 10, 2016, we announced the trial had met its primary endpoint of reduction in clinical cardiac events and that the incidence of adverse events, including serious adverse events, in patients treated with ixmyelocel-T was comparable to patients in the placebo group. Patients were then followed for an additional 12 months for safety. Because the trial met the primary endpoint, patients who received placebo or were randomized to ixmyelocel-T in the double-blind portion of the trial but did not receive ixmyelocel-T were offered the option to receive ixmyelocel-T. We successfully treated the last patients in February 2017, and the last follow-up visit occurred approximately one year later. In addition, we have conducted clinical studies for the treatment of critical limb ischemia, and an ixmyelocel-T investigator-initiated clinical study was conducted for the treatment of craniofacial reconstruction.

On September 29, 2017, the FDA indicated we would be required to conduct at least one additional Phase 3 clinical study to support a BLA for ixmyelocel-T. Given the expense required to conduct further development and our focus on growing our existing commercial products, at this time we have no current plans to initiate or fund a Phase 3 trial on our own.

### Results of Operations

#### Net Loss

Our net loss for the three months ended March 31, 2019 and 2018 totaled $2.8 million and $7.7 million, respectively.

*(In thousands)*

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Total revenues | $21,810 | $18,027 |
| Cost of product sales | 8,640 | 7,666 |
| Gross profit | 13,170 | 10,361 |
| Total operating expenses | 16,528 | 14,683 |
| Loss from operations | (3,358) | (4,322) |
| Other income (expense) | 514 | (3,337) |
| Net loss | $(2,844) | $(7,659) |

#### Net Revenues

Net revenues increased for the three months ended March 31, 2019 compared to the same period the previous year as an increase in cartilage implants more than offset a reduction in Epicel grafts in the quarter compared to the prior year.

| Revenue by product (in thousands) | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| MACI | $16,583 | $12,055 |
| Epicel | 5,227 | 5,972 |
| Total Revenue | $21,810 | $18,027 |

19

*Seasonality.* Over the last four years ACI (MACI and Carticel prior to its replacement) sales volumes from the first through the fourth quarter have on average represented 20%, 24%, 22% and 35% respectively, of total annual volumes. MACI orders are stronger in the fourth quarter due to a number of factors including insurance copay limits and the time of year patients prefer to start rehabilitation. Epicel revenue is also subject to seasonal fluctuations mostly associated with the use of heating elements during the colder months, with stronger sales occurring in the winter months of the first and fourth quarters, and weaker sales occurring in the hot summer months of the third quarter. However, in any single year, this trend can be absent due to the extreme variability inherent with Epicel’s patient volume. Over the last four years the percentage of annual product orders for Epicel has on average been 28%, 25%, 21% and 27% from the first to the fourth quarters.

#### Gross Profit and Gross Profit Ratio

*(In thousands)*

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Gross profit | $13,170 | $10,361 |
| Gross profit % | 60% | 57% |

Gross profit increased for the three months ended March 31, 2019 compared to the same period in 2018 due primarily to an increase in MACI sales combined with our highly fixed manufacturing cost structure which consists mainly of labor and facility costs that do not materially fluctuate with volume increases.

#### Research and Development Costs

*(In thousands)*

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Research and development costs | $3,008 | $3,729 |

The following table summarizes the approximate allocation of cost for our research and development projects:

*(In thousands)*

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Dilated Cardiomyopathy | $32 | $556 |
| MACI | 2,130 | 2,456 |
| Epicel | 846 | 717 |
| Total research and development costs | $3,008 | $3,729 |

Research and development costs for the three months ended March 31, 2019 were $3.0 million versus $3.7 million for the same period a year ago. These expenses include research costs associated with manufacturing process improvement activities, the ongoing MACI pediatric trial, pharmacovigilance and other reporting and compliance requirements, as well as medical affairs and external grants. The reduction was driven by clinical study start-up costs related to the MACI pediatric trial incurred in 2018 and a reduction to other outside expenditures compared to prior year.

#### Selling, General and Administrative Costs

*(In thousands)*

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Selling, general and administrative costs | $13,520 | $10,954 |

Selling, general and administrative costs for the three months ended March 31, 2019 were $13.5 million compared to $11.0 million for the same period a year ago. The increase in selling, general and administrative costs for the three months ended March 31, 2019 is due primarily to a $1.1 million increase in stock based compensation expenses, an incremental $0.6 million in MACI sales force expenses driven by the expansion in the second quarter of 2018 and a $0.6 million increase in selling expenses and patient reimbursement support services. The increase in selling expenses and patient reimbursement support services is primarily driven by higher MACI sales volume and the revision to our distributor model as of June 15, 2018, compared to the same period a year ago.

#### Other Income (Expense)

*(In thousands)*

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Decrease (increase) in fair value of warrants | $— | $(2,907) |
| Other income | 36 | 2 |
| Net interest income (expense) | 478 | (432) |
| Total other expense | $514 | $(3,337) |

The change in other income and expense is due to the increase in our stock price in 2018 resulting in an increase in the fair value of warrants compared to no expense or income due to a change in the fair value of warrants in 2019. We did not experience a change in warrant value for the three months ended March 31, 2019 due to the expiration of the 2013 warrants in 2018 which contributed to the valuation change. In addition, all outstanding debt was repaid in December 2018. The interest income for the three months ended March 31, 2019 is a result of our investments in various marketable debt securities.

#### Stock Compensation

Non-cash stock-based compensation expense included in cost of goods sold, research and development expenses and selling, general and administrative expenses is summarized in the following table:

*(In thousands)*

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Cost of goods sold | $260 | $142 |
| Research and development | 525 | 475 |
| Selling, general and administrative | 1,843 | 725 |
| Total non-cash stock-based compensation expense | $2,628 | $1,342 |

The changes in stock-based compensation expense are due primarily to fluctuations in the fair value of the options granted in 2019 compared to 2018 as a result in the increase in stock price. In addition, we granted restricted stock units in 2019 and none in 2018.

### Liquidity and Capital Resources

Since the acquisition in 2014 of MACI, Epicel and Carticel from Sanofi, our primary focus has been to invest in our existing commercial business with the goal of growing revenue. We have raised significant funds in order to complete our product development programs, and complete clinical trials needed to market and commercialize our products. To date, we have financed our operations primarily through public and private sales of our equity securities. At present revenue levels, we do not currently anticipate the need to finance our operations through the sales of equity securities.

Our cash and cash equivalents totaled $35.1 million, and short term investments totaled $49.0 million as of March 31, 2019. The cash provided by operations of $0.2 million was a result of a net loss of $2.8 million, offset largely by collections on prior quarter sales and by noncash charges including $2.6 million of stock compensation expense, $0.2 million due to the amortization of premiums and discounts on marketable securities and $0.3 million of depreciation expense.

Our cash and cash equivalents totaled $29.8 million as of March 31, 2018. During the three months ended March 31, 2018, the cash provided by operations was $0.4 million was a result of a net loss of $7.7 million. The cash provided by operations was offset by collections on prior quarter sales and noncash charges including $1.3 million of stock compensation expense, $2.9 million due to the change in fair value of warrants and $0.4 million of depreciation expense.

The change in cash used for investing activities as of March 31, 2019 is the result of $10.7 million in short term investments purchases offset by $26.6 million of short term investment maturities and property plant and equipment purchases of $0.2 million primarily for manufacturing upgrades and leasehold improvements through March 31, 2019. The change in cash used for investing activities is the result of the purchases of $0.2 million of property plant and equipment for manufacturing upgrades through March 31, 2018.

The change in cash provided from financing activities is the result of net proceeds from the exercise of stock options of $1.0 million during the three months ended March 31, 2019. The change in cash provided from financing activities is the result of proceeds from the exercise of stock options of $1.0 million and exercise of warrants of $1.7 million during the three months ended March 31, 2018.

We believe that, based on current revenue levels, cash on hand, cash equivalents and short term investments we are in a position to operate our business without the need to finance our operations through the sales of equity securities. If revenues decline for a sustained period of time, we may need to access additional capital; however, we may not be able to obtain financing on acceptable terms or at all. The terms of any financing may adversely affect the holdings or the rights of our shareholders. Actual cash requirements may differ from projections and will depend on many factors, including the level of future research and development, the scope and results of ongoing and potential clinical trials, the costs involved in filing, prosecuting and enforcing patents, the need for additional manufacturing capacity, competing technological and market developments, costs of possible acquisition or development of complementary business activities, and the cost to market our products.

### Off-Balance Sheet Arrangements

At March 31, 2019, we were not party to any off-balance sheet arrangements.

### Critical Accounting Policies

Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these condensed consolidated financial statements requires the application of appropriate technical accounting rules and guidance, as well as the use of estimates. The application of these policies necessarily involves judgments regarding future events. These estimates and judgments, in and of themselves, could materially impact the condensed consolidated financial statements and disclosures based on varying assumptions. The accounting policies discussed in our Form 10-K for the fiscal year ended December 31, 2018 are considered by management to be the most important to an understanding of the consolidated financial statements because of their significance to the portrayal of our financial condition and results of operations. There have been no material changes to that information disclosed in our Annual Report during the three months ended March 31, 2019.

### Forward-Looking Statements

This report, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “estimates,” “plans,” “projects,” “trends,” “opportunity,” “current,” “intention,” “position,” “assume,” “potential,” “outlook,” “remain,” “continue,” “maintain,” “sustain,” “seek,” “achieve,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. The factors described in our Annual Report, among others, could have a material adverse effect upon our business, results of operations and financial conditions.

Because the factors referred to in the preceding paragraph could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements we make, you should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These forward-looking statements include statements regarding:

- manufacturing and facility capabilities;
- potential strategic collaborations with others;
- future capital needs and financing sources;
- adequacy of existing capital to support operations for a specified time;
- reimbursement for our products;
- product development and marketing plans;
- features and successes of our cellular therapies;
- clinical trial plans, including publication thereof;
- anticipation of future losses;
- replacement of manufacturing sources;
- commercialization plans; or
- revenue expectations and operating results.

## Market risk

As filed, 429 characters.

As of March 31, 2019, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates or credit conditions on our securities portfolio. For additional information regarding our market risk, refer to Item 7A. Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2018.

## Controls and procedures

As filed, 1,685 characters.

### Evaluation of Disclosure Controls and Procedures

The Company has established disclosure controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer (its “Certifying Officers”), as appropriate, to allow timely decisions regarding required disclosure.

Management of the Company, with the participation of its Certifying Officers, evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rules l3a-15(e) and l5d-15(e) under the Exchange Act. Based on the evaluation as of March 31, 2019, our Certifying Officers concluded that the Company’s disclosure controls and procedures were effective.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2019, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We implemented internal controls to ensure management properly assessed the impact of the new lease accounting standards on our condensed consolidated financial statements to facilitate adoption of the new leasing standards effective January 1, 2019. There were no significant changes to our internal control over financial reporting due to the adoption of the new standards.

## Risk factors

As filed, 471 characters.

There have been no material changes from the risk factors previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2018. The risks described in the Annual Report on Form 10-K are not the only risks the Company faces. Additional risks and uncertainties not currently known or currently deemed to be immaterial also may materially and adversely affect the Company’s business, financial condition, results of operations or cash flows.

Filed May 7, 2019.
Source: SEC EDGAR, the filing index for accession 0001628280-19-006102. Last ingested by Listed: Nov 14, 2026, 12:33 ET. No prices; not investment advice.
